CJC-1295 (No DAC) vs CJC-1295 + Ipamorelin: Mechanism, Half-Life & Research Use

Direct Comparison: CJC-1295 (No DAC) vs. CJC-1295 + Ipamorelin

CJC-1295 (No DAC) is a 29-amino acid growth-hormone-releasing hormone (GHRH) analog that binds selectively to GHRH receptors, stimulating pulsatile growth hormone synthesis. In contrast, CJC-1295 + Ipamorelin combines this GHRH analog with a selective ghrelin/growth hormone secretagogue receptor (GHS-R1a) agonist, triggering dual signal transduction pathways that generate a synergistic, amplified release of growth hormone in preclinical models.

While CJC-1295 (No DAC) operates through a single endocrine axis to elevate basal endogenously regulated secretion, the combination sequence engages both GHRH-R and GHS-R1a simultaneously. This co-activation bypasses somatostatin-mediated inhibition to a greater degree than single-agent administration, resulting in significantly higher transient peak concentrations of growth hormone and downstream insulin-like growth factor 1 (IGF-1) without inducing somatotroph desensitization.

Comparative Specifications and Criteria Table

To assist research institutions in selecting the appropriate peptide configuration for in vitro assays or animal models, the baseline physical and mechanistic parameters of both configurations are outlined in the comparison criteria below.

• Receptor Target: CJC-1295 (No DAC) targets GHRH-R exclusively; CJC-1295 + Ipamorelin targets GHRH-R and GHS-R1a concurrently. • Mechanistic Class: CJC-1295 (No DAC) is a GHRH Analog (Tetrasubstituted GRF 1-29); CJC-1295 + Ipamorelin is a Dual-Action GHRH Analog / GHRP Secretagogue Complex. • Reported Half-Life: CJC-1295 (No DAC) exhibits a half-life of ~30 minutes in rodent models; Ipamorelin exhibits a half-life of ~2 hours, maintaining distinct clearance kinetics. • Solubility: Both configurations demonstrate rapid dissolution in sterile bacteriostatic water or standard aqueous phosphate buffers (pH 6.0–7.4). • Typical Preclinical Model: Single-agent CJC-1295 (No DAC) is utilized in baseline somatotroph receptor mapping and linear signaling assays; the combination sequence is applied in high-yield tissue repair, body composition, and synergistic endocrine pathway trials. • Vial Sizes Available: Standard laboratory formats include 2mg and 5mg single-agent vials of CJC-1295 (No DAC) lyophilized powder, as well as blended 5mg and 10mg dual-peptide research vials.

Researchers conducting high-throughput screening or precise dose-response curves can cross-reference batch specifications via our verified third-party Certificates of Analysis to confirm lot-to-lot consistency before initiating trial protocols.

Mechanism of Action: CJC-1295 (No DAC) as a Selective GHRH Analog

CJC-1295 (No DAC), also recognized as Modified GRF (1-29), is a synthetic derivative of native growth-hormone-releasing hormone. The sequence incorporates four amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) designed to resist enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). As a selective GHRH analog, it binds to the GHRH receptor on anterior pituitary somatotrophs, activating the Gs alpha subunit signaling pathway. This stimulates adenylate cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA).

Preclinical studies suggest that this cascade promotes both transcription of the growth hormone gene and exocytosis of pre-stored growth hormone vesicles. Because CJC-1295 (No DAC) lacks the Drug Affinity Complex (DAC) maleimide moiety, it does not form covalent bonds with circulating serum albumin. Consequently, its duration of action remains limited to a short, physiological pulse (~30 minutes), mimicking the endogenous secretion dynamics observed in intact mammalian systems.

As a long-acting growth-hormone-releasing hormone relative to native GHRH, CJC-1295 (No DAC) sustains elevated baseline GH and downstream IGF-1 levels for tissue repair research without inducing continuous, non-physiologic elevation that could lead to receptor down-regulation or pituitary exhaustion.

Synergistic Dynamics: The CJC-1295 + Ipamorelin Dual-Receptor Axis

When CJC-1295 (No DAC) is evaluated in combination with the pentapeptide Ipamorelin peptide, researchers observe a distinct mechanistic synergy. While CJC-1295 (No DAC) stimulates the GHRH receptor pathway, Ipamorelin selectively targets the growth hormone secretagogue receptor (GHS-R1a), a G-protein coupled receptor operating via the Gq/11 subunit pathway. Activation of GHS-R1a triggers phospholipase C (PLC), generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilizes intracellular calcium stores.

In vitro data indicate that the simultaneous activation of cAMP-dependent PKA pathways (via CJC-1295) and calcium-dependent PKC pathways (via Ipamorelin) produces a supracomparative increase in growth hormone vesicle release compared to the mathematical sum of either compound administered in isolation. Furthermore, Ipamorelin acts as a functional antagonist against somatostatin—the primary inhibitory hormone that curtails GH release. By suppressing somatostatin signaling while concurrently activating GHRH-R and GHS-R1a, the dual formulation induces robust, pulsatile GH amplification while preserving endogenous negative feedback loops.

Importantly, preclinical models demonstrate that Ipamorelin maintains exceptional selectivity for GHS-R1a, avoiding the off-target elevation of adrenocorticotropic hormone (ACTH), cortisol, or prolactin frequently observed with first-generation secretagogues.

Pharmacokinetics, Half-Life, and Secretion Dynamics

Understanding the kinetic variances between single-agent CJC-1295 (No DAC) and the CJC-1295 + Ipamorelin combination is critical for establishing valid sampling schedules in preclinical research. CJC-1295 (No DAC) exhibits rapid plasma clearance following parenteral administration in animal models, reaching peak plasma concentrations (Cmax) within 15 to 20 minutes and declining with an elimination half-life of approximately 30 minutes. This rapid clearance profile produces a sharp, transient growth hormone spike that returns to baseline within 2 to 3 hours.

Conversely, Ipamorelin possesses a longer terminal half-life of approximately 120 minutes in rodent models. When administered concurrently, the combined profile exhibits biphasic absorption and clearance dynamics. CJC-1295 initiates immediate adenylate cyclase activation, triggering rapid vesicle exocytosis, while Ipamorelin maintains sustained intracellular calcium elevation and somatostatin suppression. This dual-phase kinetic profile extends the window of GH release without converting the pulsatile secretion into continuous tonic elevation.

Researchers designing kinetic assays can reference compound-specific parameters across our comprehensive research peptide catalog to coordinate precise blood sampling timeframes or cellular incubation intervals.

Somatotroph Activation and Downstream IGF-1 Expression

Growth hormone secreted by anterior pituitary somatotrophs travels through circulation to bind hepatic GH receptors, triggering the JAK/STAT signaling cascade that drives gene expression and secretion of insulin-like growth factor 1 (IGF-1). Both CJC-1295 (No DAC) and the CJC-1295 + Ipamorelin combination are widely studied in preclinical models for their capacity to elevate systemic IGF-1 levels, which mediate peripheral tissue repair, skeletal muscle protein synthesis, and extracellular matrix remodeling.

In animal models evaluating muscle repair and metabolic homeostasis, single-agent CJC-1295 (No DAC) demonstrates steady, moderate elevations in circulating IGF-1 concentrations over 24-hour observation windows. However, the CJC-1295 + Ipamorelin blend elicits significantly higher peak IGF-1 levels due to the initial magnitude of the GH pulse. Preclinical literature suggests that higher amplitude GH pulses provide a stronger inductive signal for hepatic IGF-1 transcript synthesis, making the dual blend a frequent subject of study in accelerated collagen deposition and cellular regeneration experiments.

GHRH Analogs and GH Secretagogues in Preclinical Research

To contextualize where CJC-1295 (No DAC) and CJC-1295 + Ipamorelin fit within the broader landscape of somatotropic research, it is helpful to examine related compounds within the GHRH and GH secretagogue classes. For instance, researchers investigating sustained, long-term GHRH receptor occupancy often evaluate CJC-1295 with DAC, which incorporates a covalent bioconjugation site that extends its plasma half-life to several days in rodent models. Alternatively, studies focusing specifically on visceral adiposity and selective pituitary stimulation may utilize the GHRH derivative Tesamorelin research compound, which features an N-terminal modification optimized for metabolic lipid oxidation research.

When designing trials that require short-acting, physiological secretagogue activity, single-agent CJC-1295 (No DAC) offers isolated GHRH-R activation without confounding secondary receptor pathways. However, when the study objective requires maximal physiological GH release without elevated cortisol or prolactin, combining CJC-1295 (No DAC) with Ipamorelin provides a superior mechanistic model compared to older secretagogues such as GHRP-6 or GHRP-2, which demonstrate broader off-target receptor activation.

Analyzing these distinct molecular structures within our wider PX1 Research database allows investigative teams to select the exact secretagogue axis required for their experimental framework.

Matching the Peptide Configuration to Laboratory Objectives

Selecting between CJC-1295 (No DAC) as a single agent or the CJC-1295 + Ipamorelin combination depends directly on the parameters of the experimental design. Investigators must weigh the requirement for single-receptor isolation against the goal of maximal intracellular signaling amplification.

CJC-1295 (No DAC) is ideal for: • Baseline GHRH receptor binding and affinity assays. • Research isolating the cAMP/PKA pathway without calcium-channel cross-talk. • Studies evaluating normal, un-amplified pituitary pulse frequency. • Models where secondary secretagogue exposure must be excluded.

CJC-1295 + Ipamorelin is ideal for: • Preclinical tissue repair and wound healing models requiring maximal IGF-1 production. • Body composition, nitrogen retention, and sarcopenia research in animal models. • In vitro experiments investigating GHRH-R and GHS-R1a receptor cross-talk. • Comparative studies analyzing somatostatin override dynamics.

Institutions scaling up trial parameters or establishing longitudinal rodent cohorts can access our bulk institutional procurement program to ensure standardized lot allocation across multi-phase study protocols.

Reconstitution, Stability, and Laboratory Handling

Both CJC-1295 (No DAC) and Ipamorelin are supplied as lyophilized (freeze-dried) powders to ensure structural stability during transport and storage. Lyophilized cakes should be stored at -20°C prior to reconstitution to prevent hydrolytic degradation or peptide aggregation.

For laboratory reconstitution, researchers should utilize sterile Bacteriostatic Water (0.9% benzyl alcohol) or standard sterile saline depending on the downstream assay requirements. Reconstitution should be performed by gently introducing the solvent along the inner wall of the glass vial, avoiding high-shear agitation or vigorous shaking, which can disrupt delicate secondary peptide structures. Once reconstituted, solution aliquots should be refrigerated at 2°C to 8°C and utilized within 30 days, or flash-frozen for longer-term single-use storage.

To calculate precise volumetric concentrations and molarities for research protocols, laboratory personnel are encouraged to utilize our interactive laboratory reconstitution calculator.

Analytical Quality Control: HPLC, Mass Spectrometry, and Endotoxin Limits

Reliable preclinical outcomes depend entirely on the chemical purity and structural integrity of the research compounds tested. PX1 Research enforces strict quality control standards for every lot of CJC-1295 (No DAC) and CJC-1295 + Ipamorelin produced in our USA-based, GMP-compliant manufacturing facilities.

Every batch undergoes rigorous chemical validation in an ISO 17025 accredited analytical laboratory. High-Performance Liquid Chromatography (HPLC) is conducted to verify chemical purity levels exceeding 99.0%, ensuring the absence of truncated sequences or synthesis side-products. Liquid Chromatography-Mass Spectrometry (LC-MS) confirms exact molecular mass and sequence fidelity.

Furthermore, because bacterial endotoxins can induce fever, inflammatory cytokine release, or altered physiological responses in animal models, all PX1 peptides undergo quantitative Chromogenic LAL Endotoxin Testing to ensure levels fall strictly below standard research safety thresholds (<0.01 EU/μg). All orders are shipped rapidly from our California and Arizona logistics facilities with same-day fulfillment on business days.